The ErbB kinase domain: Structural perspectives into kinase activation and inhibition

Ron Bose, Xuewu Zhang

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) and its family members, ErbB2, ErbB3 and ErbB4, are receptor tyrosine kinases which send signals into the cell to regulate many critical processes including development, tissue homeostasis, and tumorigenesis. Central to the signaling of these receptors is their intracellular kinase domain, which is activated by ligand-induced dimerization of the receptor and phosphorylates several tyrosine residues in the C-terminal tail. The phosphorylated tail then recruits other signaling molecules and relays the signal to downstream pathways. A model of the autoinhibition, activation and feedback inhibition mechanisms for the ErbB kinase domain has emerged from a number of recent structural studies. Meanwhile, recent clinical studies have revealed the relationship between specific ErbB kinase mutations and the responsiveness to kinase inhibitor drugs.We will review these regulation mechanisms of the ErbB kinase domain, and discuss the binding specificity of kinase inhibitors and the effects of kinase domain mutations found in cancer patients from a structural perspective.

Original languageEnglish (US)
Pages (from-to)649-658
Number of pages10
JournalExperimental Cell Research
Volume315
Issue number4
DOIs
StatePublished - Feb 15 2009

Fingerprint

Phosphotransferases
Mutation
Receptor Protein-Tyrosine Kinases
Dimerization
Inhibition (Psychology)
Epidermal Growth Factor Receptor
Tyrosine
Carcinogenesis
Homeostasis
Ligands
Pharmaceutical Preparations
Neoplasms

Keywords

  • Activation loop
  • Epidermal growth factor receptor
  • Growth factor receptor
  • Lung cancer
  • MIG6
  • Receptor dimerization
  • Receptor tyrosine kinase
  • Signal transduction
  • Structural biology
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Cell Biology

Cite this

The ErbB kinase domain : Structural perspectives into kinase activation and inhibition. / Bose, Ron; Zhang, Xuewu.

In: Experimental Cell Research, Vol. 315, No. 4, 15.02.2009, p. 649-658.

Research output: Contribution to journalArticle

@article{8dcc77b16a614bf39b1efe971fe48b32,
title = "The ErbB kinase domain: Structural perspectives into kinase activation and inhibition",
abstract = "Epidermal growth factor receptor (EGFR) and its family members, ErbB2, ErbB3 and ErbB4, are receptor tyrosine kinases which send signals into the cell to regulate many critical processes including development, tissue homeostasis, and tumorigenesis. Central to the signaling of these receptors is their intracellular kinase domain, which is activated by ligand-induced dimerization of the receptor and phosphorylates several tyrosine residues in the C-terminal tail. The phosphorylated tail then recruits other signaling molecules and relays the signal to downstream pathways. A model of the autoinhibition, activation and feedback inhibition mechanisms for the ErbB kinase domain has emerged from a number of recent structural studies. Meanwhile, recent clinical studies have revealed the relationship between specific ErbB kinase mutations and the responsiveness to kinase inhibitor drugs.We will review these regulation mechanisms of the ErbB kinase domain, and discuss the binding specificity of kinase inhibitors and the effects of kinase domain mutations found in cancer patients from a structural perspective.",
keywords = "Activation loop, Epidermal growth factor receptor, Growth factor receptor, Lung cancer, MIG6, Receptor dimerization, Receptor tyrosine kinase, Signal transduction, Structural biology, Tyrosine kinase inhibitor",
author = "Ron Bose and Xuewu Zhang",
year = "2009",
month = "2",
day = "15",
doi = "10.1016/j.yexcr.2008.07.031",
language = "English (US)",
volume = "315",
pages = "649--658",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - The ErbB kinase domain

T2 - Structural perspectives into kinase activation and inhibition

AU - Bose, Ron

AU - Zhang, Xuewu

PY - 2009/2/15

Y1 - 2009/2/15

N2 - Epidermal growth factor receptor (EGFR) and its family members, ErbB2, ErbB3 and ErbB4, are receptor tyrosine kinases which send signals into the cell to regulate many critical processes including development, tissue homeostasis, and tumorigenesis. Central to the signaling of these receptors is their intracellular kinase domain, which is activated by ligand-induced dimerization of the receptor and phosphorylates several tyrosine residues in the C-terminal tail. The phosphorylated tail then recruits other signaling molecules and relays the signal to downstream pathways. A model of the autoinhibition, activation and feedback inhibition mechanisms for the ErbB kinase domain has emerged from a number of recent structural studies. Meanwhile, recent clinical studies have revealed the relationship between specific ErbB kinase mutations and the responsiveness to kinase inhibitor drugs.We will review these regulation mechanisms of the ErbB kinase domain, and discuss the binding specificity of kinase inhibitors and the effects of kinase domain mutations found in cancer patients from a structural perspective.

AB - Epidermal growth factor receptor (EGFR) and its family members, ErbB2, ErbB3 and ErbB4, are receptor tyrosine kinases which send signals into the cell to regulate many critical processes including development, tissue homeostasis, and tumorigenesis. Central to the signaling of these receptors is their intracellular kinase domain, which is activated by ligand-induced dimerization of the receptor and phosphorylates several tyrosine residues in the C-terminal tail. The phosphorylated tail then recruits other signaling molecules and relays the signal to downstream pathways. A model of the autoinhibition, activation and feedback inhibition mechanisms for the ErbB kinase domain has emerged from a number of recent structural studies. Meanwhile, recent clinical studies have revealed the relationship between specific ErbB kinase mutations and the responsiveness to kinase inhibitor drugs.We will review these regulation mechanisms of the ErbB kinase domain, and discuss the binding specificity of kinase inhibitors and the effects of kinase domain mutations found in cancer patients from a structural perspective.

KW - Activation loop

KW - Epidermal growth factor receptor

KW - Growth factor receptor

KW - Lung cancer

KW - MIG6

KW - Receptor dimerization

KW - Receptor tyrosine kinase

KW - Signal transduction

KW - Structural biology

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=62649103876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62649103876&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2008.07.031

DO - 10.1016/j.yexcr.2008.07.031

M3 - Article

C2 - 18761339

AN - SCOPUS:62649103876

VL - 315

SP - 649

EP - 658

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 4

ER -